JP2005508893A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005508893A5 JP2005508893A5 JP2003522551A JP2003522551A JP2005508893A5 JP 2005508893 A5 JP2005508893 A5 JP 2005508893A5 JP 2003522551 A JP2003522551 A JP 2003522551A JP 2003522551 A JP2003522551 A JP 2003522551A JP 2005508893 A5 JP2005508893 A5 JP 2005508893A5
- Authority
- JP
- Japan
- Prior art keywords
- fucan
- pharmaceutical composition
- use according
- effective amount
- therapeutically effective
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 18
- 239000003814 drug Substances 0.000 claims 13
- 239000002552 dosage form Substances 0.000 claims 8
- 238000004519 manufacturing process Methods 0.000 claims 8
- 206010003246 arthritis Diseases 0.000 claims 5
- 239000003795 chemical substances by application Substances 0.000 claims 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims 5
- 229920000855 Fucoidan Polymers 0.000 claims 4
- 201000004681 Psoriasis Diseases 0.000 claims 4
- 229940079593 drug Drugs 0.000 claims 4
- 208000024891 symptom Diseases 0.000 claims 4
- 241001465754 Metazoa Species 0.000 claims 3
- 108091034117 Oligonucleotide Proteins 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 239000006072 paste Substances 0.000 claims 3
- 229920000642 polymer Polymers 0.000 claims 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims 2
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 claims 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims 2
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 claims 2
- 102000053642 Catalytic RNA Human genes 0.000 claims 2
- 108090000994 Catalytic RNA Proteins 0.000 claims 2
- 229920001661 Chitosan Polymers 0.000 claims 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 2
- MJVAVZPDRWSRRC-UHFFFAOYSA-N Menadione Chemical compound C1=CC=C2C(=O)C(C)=CC(=O)C2=C1 MJVAVZPDRWSRRC-UHFFFAOYSA-N 0.000 claims 2
- 239000002202 Polyethylene glycol Substances 0.000 claims 2
- 229940048053 acrylate Drugs 0.000 claims 2
- 229940072056 alginate Drugs 0.000 claims 2
- 229920000615 alginic acid Polymers 0.000 claims 2
- 235000010443 alginic acid Nutrition 0.000 claims 2
- 239000000074 antisense oligonucleotide Substances 0.000 claims 2
- 238000012230 antisense oligonucleotides Methods 0.000 claims 2
- QZPQTZZNNJUOLS-UHFFFAOYSA-N beta-lapachone Chemical compound C12=CC=CC=C2C(=O)C(=O)C2=C1OC(C)(C)CC2 QZPQTZZNNJUOLS-UHFFFAOYSA-N 0.000 claims 2
- 229920002678 cellulose Polymers 0.000 claims 2
- 239000001913 cellulose Substances 0.000 claims 2
- 239000000499 gel Substances 0.000 claims 2
- 229920002674 hyaluronan Polymers 0.000 claims 2
- 229960003160 hyaluronic acid Drugs 0.000 claims 2
- 239000007943 implant Substances 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- KQPYUDDGWXQXHS-UHFFFAOYSA-N juglone Chemical compound O=C1C=CC(=O)C2=C1C=CC=C2O KQPYUDDGWXQXHS-UHFFFAOYSA-N 0.000 claims 2
- 239000007788 liquid Substances 0.000 claims 2
- 239000004005 microsphere Substances 0.000 claims 2
- -1 plumbazine Chemical compound 0.000 claims 2
- 229920001983 poloxamer Polymers 0.000 claims 2
- 229920001223 polyethylene glycol Polymers 0.000 claims 2
- 108091092562 ribozyme Proteins 0.000 claims 2
- 239000007921 spray Substances 0.000 claims 2
- 238000001356 surgical procedure Methods 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 238000011200 topical administration Methods 0.000 claims 2
- 208000031295 Animal disease Diseases 0.000 claims 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 claims 1
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 claims 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims 1
- 108010036949 Cyclosporine Proteins 0.000 claims 1
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 claims 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 1
- 229930012538 Paclitaxel Natural products 0.000 claims 1
- VYTBDSUNRJYVHL-UHFFFAOYSA-N beta-Hydrojuglone Natural products O=C1CCC(=O)C2=C1C=CC=C2O VYTBDSUNRJYVHL-UHFFFAOYSA-N 0.000 claims 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims 1
- 229940127093 camptothecin Drugs 0.000 claims 1
- 229960001265 ciclosporin Drugs 0.000 claims 1
- 229960001338 colchicine Drugs 0.000 claims 1
- 239000006071 cream Substances 0.000 claims 1
- 229930182912 cyclosporin Natural products 0.000 claims 1
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 claims 1
- 229960003668 docetaxel Drugs 0.000 claims 1
- 229960004679 doxorubicin Drugs 0.000 claims 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims 1
- 229960005420 etoposide Drugs 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 229960000485 methotrexate Drugs 0.000 claims 1
- 229960001156 mitoxantrone Drugs 0.000 claims 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 229960001592 paclitaxel Drugs 0.000 claims 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims 1
- 150000004492 retinoid derivatives Chemical class 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 229960002930 sirolimus Drugs 0.000 claims 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 claims 1
- 229960001940 sulfasalazine Drugs 0.000 claims 1
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 claims 1
- 238000013268 sustained release Methods 0.000 claims 1
- 239000012730 sustained-release form Substances 0.000 claims 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 1
- 235000012711 vitamin K3 Nutrition 0.000 claims 1
- 239000011652 vitamin K3 Substances 0.000 claims 1
- 229940041603 vitamin k 3 Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31536201P | 2001-08-29 | 2001-08-29 | |
| US60/315,362 | 2001-08-29 | ||
| PCT/CA2002/001337 WO2003018033A1 (en) | 2001-08-29 | 2002-08-29 | Use of fucans in the treatment of adhesions, arthritis and psoriasis |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009170270A Division JP2009280597A (ja) | 2001-08-29 | 2009-07-21 | 乾癬の治療へのフカン類の使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005508893A JP2005508893A (ja) | 2005-04-07 |
| JP2005508893A5 true JP2005508893A5 (https=) | 2006-01-05 |
| JP4758063B2 JP4758063B2 (ja) | 2011-08-24 |
Family
ID=23224048
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003522551A Expired - Lifetime JP4758063B2 (ja) | 2001-08-29 | 2002-08-29 | 癒着、関節炎及び乾癬の治療へのフカン類の使用 |
| JP2009170270A Withdrawn JP2009280597A (ja) | 2001-08-29 | 2009-07-21 | 乾癬の治療へのフカン類の使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009170270A Withdrawn JP2009280597A (ja) | 2001-08-29 | 2009-07-21 | 乾癬の治療へのフカン類の使用 |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US6812220B2 (https=) |
| EP (1) | EP1420801B1 (https=) |
| JP (2) | JP4758063B2 (https=) |
| KR (2) | KR20090019926A (https=) |
| CN (2) | CN101028283A (https=) |
| AT (1) | ATE376835T1 (https=) |
| AU (1) | AU2002325113B2 (https=) |
| CA (1) | CA2458853C (https=) |
| DE (1) | DE60223262T2 (https=) |
| DK (1) | DK1420801T3 (https=) |
| ES (1) | ES2295386T3 (https=) |
| MX (1) | MXPA04001876A (https=) |
| NZ (2) | NZ532015A (https=) |
| PT (1) | PT1420801E (https=) |
| WO (1) | WO2003018033A1 (https=) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6632456B1 (en) * | 1993-06-24 | 2003-10-14 | Astrazeneca Ab | Compositions for inhalation |
| US7595378B2 (en) | 2001-06-13 | 2009-09-29 | Genmab A/S | Human monoclonal antibodies to epidermal growth factor receptor (EGFR) |
| US8163726B2 (en) * | 2002-09-18 | 2012-04-24 | University Of Pennsylvania | Method of inhibiting choroidal neovascularization |
| US6982298B2 (en) | 2003-01-10 | 2006-01-03 | The Cleveland Clinic Foundation | Hydroxyphenyl cross-linked macromolecular network and applications thereof |
| US8137688B2 (en) | 2003-01-10 | 2012-03-20 | The Cleveland Clinic Foundation | Hydroxyphenyl cross-linked macromolecular network and applications thereof |
| US8138265B2 (en) | 2003-01-10 | 2012-03-20 | The Cleveland Clinic Foundation | Hydroxyphenyl cross-linked macromolecular network and applications thereof |
| US7465766B2 (en) | 2004-01-08 | 2008-12-16 | The Cleveland Clinic Foundation | Hydroxyphenyl cross-linked macromolecular network and applications thereof |
| WO2004078210A1 (ja) | 2003-03-06 | 2004-09-16 | Takashi Muramatsu | 開腹手術後の癒着の予防剤 |
| JP2007504273A (ja) * | 2003-05-30 | 2007-03-01 | エーアールシー ファーマシューティカルズ，インク． | 種々の作用剤を用いた、線維性癒着の抑制に関する医薬組成物及び方法 |
| CA2539324A1 (en) | 2003-09-18 | 2005-03-31 | Macusight, Inc. | Transscleral delivery |
| WO2005089800A1 (ja) * | 2004-03-17 | 2005-09-29 | Locomogene, Inc. | hsHRD3を含む医薬組成物 |
| AU2005265326B2 (en) * | 2004-07-09 | 2010-07-15 | The Cleveland Clinic Foundation | Hydroxyphenyl cross-linked macromolecular network and applications thereof |
| ES2729826T3 (es) * | 2004-09-23 | 2019-11-06 | Arc Medical Devices Inc | Composiciones farmacéuticas y métodos relacionados para inhibir adherencias fibrosas o enfermedad inflamatoria usando fucanos con bajo contenido de sulfato |
| JP4974903B2 (ja) | 2005-02-09 | 2012-07-11 | 参天製薬株式会社 | 疾患または状態を処置するための液体処方物 |
| US8663639B2 (en) | 2005-02-09 | 2014-03-04 | Santen Pharmaceutical Co., Ltd. | Formulations for treating ocular diseases and conditions |
| AU2006214892B2 (en) * | 2005-02-16 | 2013-06-27 | Kt & G Co., Ltd | Pharmaceutical composition for the treatment or prevention of diseases involving obesity, diabetes, metabolic syndrome, neuro-degenerative diseases and mitochondria dysfunction diseases |
| US20070020358A1 (en) * | 2005-03-18 | 2007-01-25 | Mower Thomas E | Sports drink concentrate |
| US20060210515A1 (en) * | 2005-03-18 | 2006-09-21 | Mower Thomas E | Hair growth formula |
| US20060210692A1 (en) * | 2005-03-18 | 2006-09-21 | Mower Thomas E | Baby food composition |
| US20060210697A1 (en) * | 2005-03-18 | 2006-09-21 | Mower Thomas E | Infant formula composition |
| US20060210514A1 (en) * | 2005-03-18 | 2006-09-21 | Mower Thomas E | Skin protection and moisturizing compositions and method of making the same |
| US20060210496A1 (en) * | 2005-03-18 | 2006-09-21 | Mower Thomas E | Compositions for skin protection from ultraviolet damage |
| US7776365B2 (en) * | 2005-03-18 | 2010-08-17 | Sakura Properties, Llc | Article with skin protecting and moisturizing compound |
| US7666448B2 (en) * | 2005-03-18 | 2010-02-23 | Sakura Properties, Llc | Skin cleansing article |
| US7749545B2 (en) * | 2005-03-18 | 2010-07-06 | Sakura Properties, Llc | Fucoidan compositions and methods for dietary and nutritional supplements |
| US20060210688A1 (en) * | 2005-03-18 | 2006-09-21 | Mower Thomas E | Dehydrated sports drink powder |
| KR101332869B1 (ko) | 2005-04-15 | 2013-11-25 | 알버트 아인슈타인 컬리지 오브 메디신 오브 예쉬바 유니버시티 | 항-ｅｇｆｒ 치료법에 속발된 피부 발진의 예방 및 치료를위한 비타민 ｋ |
| US20070003669A1 (en) * | 2005-06-02 | 2007-01-04 | Troy Kearl | Fucoidan delivery system |
| US8426381B2 (en) * | 2005-09-09 | 2013-04-23 | Lucas Meyer Cosmetics Canada Inc. | Polysaccharides compositions comprising fucans and galactans and their use to reduce extravasation and inflammation |
| WO2007092620A2 (en) | 2006-02-09 | 2007-08-16 | Macusight, Inc. | Stable formulations, and methods of their preparation and use |
| FR2897538B1 (fr) | 2006-02-23 | 2008-05-02 | Univ Paris Descartes | Utilisation de fucanes a des fins de greffe, d'ingenierie et de regeneration osseuses |
| PL2001466T3 (pl) | 2006-03-23 | 2016-06-30 | Santen Pharmaceutical Co Ltd | Rapamycyna w małej dawce do leczenia chorób związanych z przepuszczalnością naczyń |
| JP4814677B2 (ja) * | 2006-03-31 | 2011-11-16 | 株式会社荏原製作所 | 基板保持装置および研磨装置 |
| EP2043685B1 (en) | 2006-07-03 | 2015-12-23 | Genmab A/S | Prevention of rash in patients undergoing anti-egfr therapy |
| US8080260B2 (en) | 2008-02-13 | 2011-12-20 | The Cleveland Clinic Foundation | Molecular enhancement of extracellular matrix and methods of use |
| US8815953B2 (en) | 2008-03-13 | 2014-08-26 | Spectrum Pharmaceuticals, Inc. | Formulations of vitamin K analogs for topical use |
| US8410180B2 (en) | 2008-04-30 | 2013-04-02 | The Cleveland Clinic Foundation | Methods to treat urinary incontinence |
| JP5819189B2 (ja) * | 2009-03-25 | 2015-11-18 | 国立大学法人鳥取大学 | 軟骨生成促進剤および軟骨損傷由来疾病の予防治療剤 |
| JO3676B1 (ar) * | 2009-07-27 | 2020-08-27 | Arc Medical Devices Inc | مركبات صيدلانية تضم فوكانات معدلة وطرق تتعلق بها |
| KR101528265B1 (ko) * | 2010-04-16 | 2015-06-11 | 코웨이 주식회사 | 베타-라파콘을 유효성분으로 포함하는 주름개선용 화장료 조성물 |
| EP2734213B1 (en) * | 2011-07-19 | 2018-06-06 | Baxalta GmbH | Resorption enhancers as additives to improve the oral formulation of non-anticoagulant sulfated polysaccharides |
| WO2016131824A1 (en) * | 2015-02-16 | 2016-08-25 | Xantial | Composition for prevention or treatment of cutaneous disorder |
| WO2017190148A1 (en) * | 2016-04-29 | 2017-11-02 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for the prevention and treatment of surgical adhesions |
| US12186334B2 (en) | 2018-07-27 | 2025-01-07 | ARC Medical Inc. | High-molecular-weight fucans for treating fibrous adhesions and other diseases and conditions |
| BR112021000617A2 (pt) | 2018-07-27 | 2021-04-06 | Arc Medical Devices Inc. | Fucanos com elevado teor de sulfato para o tratamento de aderências fibrosas |
| MX2021000866A (es) | 2019-03-05 | 2021-06-15 | Arc Medical Devices Inc | Sistemas y metodos para la filtracion de flujo tangencial de composiciones viscosas. |
| CN111617030B (zh) * | 2020-05-22 | 2021-09-07 | 广东药科大学 | 壳寡糖口服液及其在制备减肥药物中的应用 |
| WO2025166450A1 (en) * | 2024-02-05 | 2025-08-14 | ARC Medical Inc. | Compositions, devices, systems and methods relating to improvement of range of motion in joints |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3971848A (en) * | 1970-12-21 | 1976-07-27 | Kimitsu Chemical Laboratory Co. Ltd. | Lubricating composition for mucosa or epidermis |
| JPS58147064A (ja) | 1982-02-25 | 1983-09-01 | Fuji Electric Co Ltd | トランジスタ |
| EP0293826A3 (en) | 1987-06-02 | 1989-05-10 | Stichting REGA V.Z.W. | Therapeutic and prophylactic application of sulfated polysaccharides against aids |
| JPS6431707A (en) | 1987-07-28 | 1989-02-02 | Nikko Chemicals | Dermal agent for external use |
| JPH0714850B2 (ja) | 1987-09-29 | 1995-02-22 | 喜郎 板谷 | 化粧料 |
| JPH01313433A (ja) | 1988-06-13 | 1989-12-18 | Nippon Koutai Kenkyusho:Kk | 抗ｈｉｖ剤 |
| JP2853165B2 (ja) * | 1989-05-29 | 1999-02-03 | 味の素株式会社 | 体組織癒着防止膜 |
| FR2648463B1 (fr) * | 1989-06-14 | 1993-01-22 | Inst Fs Rech Expl Mer | Polysaccharides sulfates, agent anticoagulant et agent anticomplementaire obtenus a partir de fucanes d'algues brunes et leur procede d'obtention |
| US6096722A (en) * | 1990-08-14 | 2000-08-01 | Isis Pharmaceuticals Inc. | Antisense modulation of cell adhesion molecule expression and treatment of cell adhesion molecule-associated diseases |
| US5318890A (en) * | 1991-05-06 | 1994-06-07 | The Regents Of The University Of California | Assays for inhibitors of leukocyte adhesion |
| US5605938A (en) * | 1991-05-31 | 1997-02-25 | Gliatech, Inc. | Methods and compositions for inhibition of cell invasion and fibrosis using dextran sulfate |
| JP3403496B2 (ja) | 1993-09-24 | 2003-05-06 | 株式会社ヤクルト本社 | 抗潰瘍剤およびヘリコバクター・ピロリの定着阻害剤 |
| JP3545789B2 (ja) * | 1993-09-30 | 2004-07-21 | 味の素ファルマ株式会社 | 腹腔内癒着防止剤 |
| FR2772618B1 (fr) * | 1997-12-18 | 2000-02-18 | Ifremer | Utilisation de fucane comme regulateur de la reconstruction des tissus conjonctifs |
| WO2000020642A1 (en) * | 1998-10-02 | 2000-04-13 | Genzyme Corporation | Prevention of adhesions |
| JP4267106B2 (ja) * | 1998-10-15 | 2009-05-27 | 株式会社クラレ | 癒着防止用材料 |
| JP2001052309A (ja) | 1999-08-06 | 2001-02-23 | Alps Electric Co Ltd | 薄膜磁気ヘッドおよびその製造方法 |
| SE0001631D0 (sv) * | 2000-05-04 | 2000-05-04 | Sahltech Ab | New use |
-
2002
- 2002-08-28 US US10/232,850 patent/US6812220B2/en not_active Expired - Lifetime
- 2002-08-29 ES ES02758008T patent/ES2295386T3/es not_active Expired - Lifetime
- 2002-08-29 CA CA2458853A patent/CA2458853C/en not_active Expired - Lifetime
- 2002-08-29 PT PT02758008T patent/PT1420801E/pt unknown
- 2002-08-29 NZ NZ532015A patent/NZ532015A/en not_active IP Right Cessation
- 2002-08-29 NZ NZ547609A patent/NZ547609A/en not_active IP Right Cessation
- 2002-08-29 WO PCT/CA2002/001337 patent/WO2003018033A1/en not_active Ceased
- 2002-08-29 KR KR1020097002751A patent/KR20090019926A/ko not_active Ceased
- 2002-08-29 DK DK02758008T patent/DK1420801T3/da active
- 2002-08-29 JP JP2003522551A patent/JP4758063B2/ja not_active Expired - Lifetime
- 2002-08-29 DE DE60223262T patent/DE60223262T2/de not_active Expired - Lifetime
- 2002-08-29 CN CNA200710096370XA patent/CN101028283A/zh active Pending
- 2002-08-29 CN CNB028166930A patent/CN1319540C/zh not_active Expired - Fee Related
- 2002-08-29 AU AU2002325113A patent/AU2002325113B2/en not_active Ceased
- 2002-08-29 KR KR1020047003089A patent/KR100910246B1/ko not_active Expired - Fee Related
- 2002-08-29 EP EP02758008A patent/EP1420801B1/en not_active Expired - Lifetime
- 2002-08-29 AT AT02758008T patent/ATE376835T1/de active
- 2002-08-29 MX MXPA04001876A patent/MXPA04001876A/es active IP Right Grant
-
2004
- 2004-09-13 US US10/940,413 patent/US20050074496A1/en not_active Abandoned
- 2004-10-05 US US10/958,759 patent/US7163930B2/en not_active Expired - Lifetime
-
2009
- 2009-07-21 JP JP2009170270A patent/JP2009280597A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005508893A5 (https=) | ||
| CA2458853A1 (en) | Use of fucans in the treatment of adhesions, arthritis and psoriasis | |
| Mao et al. | Targeted treatment for osteoarthritis: drugs and delivery system | |
| JP6770157B2 (ja) | 特定の投薬量の活性物質を皮膚又は粘膜に投与するための電気流体力学的に得られた繊維を含む組成物 | |
| JP6929916B2 (ja) | 適用部位における滞留時間が改善された、電気流体力学的に得られた繊維を含む医薬組成物 | |
| US9498431B2 (en) | Controlled releasing composition | |
| Riccio et al. | Exploiting polymeric films as a multipurpose drug delivery system: a review | |
| JP2005281322A (ja) | 粘膜表面への、薬学的化合物の送達に適する薬学的キャリアデバイス | |
| WO2001064214A2 (en) | Compositions and methods for the treatment of inflammatory diseases using topoisomerase inhibitors | |
| US8475823B2 (en) | Baclofen formulation in a polyorthoester carrier | |
| EP2525777A2 (en) | Material and method for treating internal cavities | |
| US20220168465A1 (en) | Biodegradable nasal splint | |
| Subramani et al. | A Novel Approach on Role of Polymers Used in Sustained Re-lease Drug Delivery System—A Review | |
| CN103263413B (zh) | 一种酮咯酸植入剂及其制备方法 | |
| CN121013711A (zh) | 用于治疗关节病诸如骨关节炎的包含秋水仙碱的关节内注射剂型 | |
| EP2889030A1 (en) | Controlling the erosion rates of mucoadhesive devices that deliver actives and other compounds and providing increased and variable therapeutic blood levels | |
| KR100885178B1 (ko) | 점착성 약제 조성물 | |
| US20230225963A1 (en) | Thermogel sustained-release microparticle-based delivery to a paranasal and/or nasal cavity | |
| Liu et al. | Orthopedic implants of ketorolac in vertebral fracture: Development, physicochemical, preclinical and clinical evaluation | |
| Gul et al. | Emerging role of chondroitin sulfate based nanocarriers in improving the therapeutic outcome of NSAIDs in the treatment of osteoarthritis through the TDDDS | |
| Papagiannopoulos et al. | Pharmaceutical applications of carrageenan | |
| Mao et al. | A review on in situ gels as polymer drug carriers in the treatment of periodontitis | |
| Shaikh et al. | A review on mucoadhesive drug delivery system | |
| Magbool et al. | Sid Ahmed | |
| Sonawane et al. | Review on Mucoadhesive Drug Delivery System |